Mirror Biologics, Inc. Announces Additional $20 Million Investment to Close Out $30 Million Series A Investment Round
Summary
Bradbury shares our vision of creating affordable and accessible next generation immunotherapy for patients suffering from refractory metastatic cancer and protecting the elderly from serious effects of respiratory viral infections. "Keith Loo, CEO of Bradbury Asset Management Fund stated: “We have been impressed with the progress made in advancing the clinical and manufacturing programs and with the talent and dedication of the Mirror Biologics team since our initial $10 million investment in December 2021. Our lead AlloStim(R) product candidate is an "off-the-shelf," non-genetically manipulated, disease agnostic, patented living immune cell derived from healthy blood donors. We specialize in the discovery, clinical testing and manufacturing of next generation therapeutic and prophylactic immunotherapy vaccine products which incorporate living immune cells as active ingredients. We are driven by compassion for patients suffering from incurable diseases and highly toxic therapies to provide non-toxic, affordable alternative immunotherapy treatment options with curative or life-extending activity that can be made widely accessible and capable of distribution to out-patient clinics in both urban and rural areas world-wide.About Bradbury GroupBradbury Group, the holding company of Bradbury Asset Management (Hong Kong) Limited, is a comprehensive financial institution consisting of several licensed professional entities that specialize in offering international securities brokerage, asset management, investment funds and wealth management services to sophisticated investors globally.